AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04451941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: RecoveriX with individual EEG calibration
Description: RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks
Study NCT04451941 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RecoveriX without individual EEG calibration
Description: RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
Study NCT01574508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transient Continuous Subcutaneous Insulin Infusion
Description: Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
Study NCT01574508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transient Multiple Daily Insulin Injections
Description: Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
Study NCT01908530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprobe glucose sensor
Description: Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
Study NCT01372969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cx601
Description: Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
Study NCT01023711 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inactivated H1N1 vaccine
Description: 0.5 ml IM into Deltoid region of arm
Study NCT01023711 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inactivated H1N1 vaccine
Description: 0.5 mL IM X 1 dose
Study NCT01941329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation (PRP)
Study NCT01941329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation (PRP)
Study NCT01941329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous injection of ranibizumab
Study NCT01717872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope blade
Description: The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
Study NCT03373929 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PFO Closure Rate
Description: Suture Mediated PFO Closure and Septal Repair
Study NCT03373929 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Published PFO Device Closure
Description: Suture Mediated PFO Closure and Septal Repair
Study NCT03560310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg twice daily and ASA 75-100 mg daily
Description: Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
Study NCT03560310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA 75-160 mg daily
Description: Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
Study NCT03400852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-1411
Description: MNK-1411 (1 mg/mL suspension) for subcutaneous injection
Study NCT03400852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo suspension for subcutaneous injection
Study NCT05134558 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Xenon-enhanced Ventilation CT-guided Radiotherapy
Description: Xenon-enhanced Ventilation CT-guided Radiotherapy for functional protection of the lung
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acti-Lance Lite
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acti-Lance Universal
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acti-Lance Special
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Super Lite
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Lite
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Universal
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Extra
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Special
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Micro Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Low Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Normal Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance High Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04127695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ABBV-0805
Description: Placebo ABBV-0805 administered by IV infusion.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Max Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Pediatric
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSafe Solo 29 Gauge
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT04001348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSafe Solo 23 Gauge
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.
Study NCT00896298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin
Description: Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
Study NCT00896298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT00494585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701
Description: 80 mg orally twice a day for 30 days
Study NCT01359345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadollinum
Description: use of on injection gadollinum Iv for imaging
Study NCT02248805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD007
Description: MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
Study NCT01578681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Expiration Open glottis inferolateral (ELTGOL)
Description: Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
Study NCT01578681 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Patient will be instructed to do muscle stretching of the thorax
Study NCT04402424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Faecal Immunochemical Testing
Description: Stool samples for both point of care and laboratory based faecal immunochemical testing via device specific sampling sticks
Study NCT00545090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 6 months
Study NCT01067274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesanoid (ATRA)
Description: 45 mg/m2/day in two divided doses from D8 to D28
Study NCT01067274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZACITIDINE (VIDAZA)
Description: 75 mg/m2/12h SC from D1 to D5
Study NCT02313246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy
Description: This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
Study NCT02468167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration
Description: Balloon-occluded retrograde transvenous obliteration
Study NCT02468167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyanoacrylate injection
Description: Endoscopic cyanoacrylate injection
Study NCT02468167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-butyl-2-cyanoacrylate
Study NCT02468167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lauromacrogol
Study NCT03309072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: active tDCS
Study NCT01067274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYTARABINE
Description: Cytarabine : 60 mg/m2/12h SC from D1 to D5
Study NCT01333228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived endothelial progenitor cells
Description: Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
Study NCT02109991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CG-100 device
Description: Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
Study NCT04280055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 0.14 mg/kg p.o. in three sessions spaced by one week
Study NCT03309072 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS
Study NCT01146340 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: 40 Gy / 5 fractions / 29 days
Study NCT04139642 — intervention group
Intervention type: DEVICE
Intervention: SimpleSway
Description: During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences.
Study NCT02868411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal Swab
Study NCT03708718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 5 mg
Description: 5mg prednisolone, once a day for 6 months
Study NCT03708718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule; From August 2020 'no additional treatment'
Description: Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
Study NCT04681105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given PO
Study NCT04681105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT04681105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given IV or PO
Study NCT04681105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab
Description: Given IV
Study NCT04681105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Given PO
Study NCT04681105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Given IV
Study NCT04110912 — intervention group
Intervention type: OTHER
Intervention: This is a registry and no interventions are taking place.
Study NCT03010319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix Dermal Repair Scaffold
Description: Application of PriMatrix to ulcer
Study NCT03010319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Secondary Dressings
Description: Dressings to ensure moist wound environment
Study NCT03010319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary Dressings
Description: Dressings to ensure moist wound environment
Study NCT03010319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading device
Description: Offloading device to decrease pressure to wound area
Study NCT03010319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Offloading device
Description: Offloading device to decrease pressure to wound area
Study NCT02366312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
Study NCT02532465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q
Study NCT02532465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Study NCT00824473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00824473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% azelastine hydrochloride
Description: 0.15% azelastine hydrochloride 822 mcg
Study NCT04222296 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fitting strategy of cohlear implant of hearing aid
Description: To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods
Study NCT03938896 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: platelet rich plasma
Description: Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged